mTOR和4E-BP1在结外鼻型NK/T细胞淋巴瘤中的表达及其与预后的关系

张强; 刘钢; 杭伟

doi:10.13201/j.issn.1001-1781.2019.02.008

mTOR和4E-BP1在结外鼻型NK/T细胞淋巴瘤中的表达及其与预后的关系

- 天津市环湖医院耳鼻咽喉科(天津, 300350)
基金项目:
天津市卫生局科技基金项目 (No:2012KZ035)

详细信息

通讯作者: 杭伟,E-mail:hangwei2627@126.com

中图分类号: R733.4

收稿日期: 2018-10-26

Expression of mTOR and 4E-BP1in extranodal Nasal-type NK/T-cell Lymphoma and implication for prognosis

- Department of Otorhinolaryngology, Huanhu Hospital, Tianjin, 300350, China

More Information

Corresponding author: HANG Wei, E-mail: hangwei2627@126.com

Received Date: 26 October 2018

摘要

摘要: 目的:研究哺乳动物雷帕霉素靶蛋白(mTOR)、真核细胞翻译起始因子4E结合蛋白-1(4E-BP1)在结外鼻型NK/T细胞淋巴瘤(ENKTCL)中的表达,及其与患者临床病理因素和预后的关系。方法:采用免疫组织化学染色方法检测36例ENKTCL和20例鼻咽淋巴组织增生患者组织中mTOR和4E-BP1蛋白的表达情况,运用χ²检验分析其与ENKTCL的临床分期、B症状、一般状况评分及国际预后指数(IPI)之间的关系。结果:ENKTCL组织中mTOR、4E-BP1表达率分别为63.9%和58.3%;鼻咽淋巴组织增生中的mTOR、4E-BP1表达率分别为15.0%和10.0%,2组比较差异均有统计学意义(χ²=12.355,P=0.0001;χ²=12.410,P=0.0001),且mTOR、4E-BP1在ENKTCL组织中表达呈正相关(r=0.655,P=0.001)。mTOR与ENKTCL的临床分期有关,且在Ⅲ~Ⅳ期组中的阳性表达率高于Ⅰ~Ⅱ期组,差异有统计学意义(χ²=17.902,P=0.0001);4E-BP1与ENKTCL的IPI有关,且IPI>2分组的阳性表达率高于IPI≤2分组,差异有统计学意义(χ²=4.051,P=0.044)。结论:mTOR与下游底物4E-BP1共同作用导致ENKTCL的生长、分化和转移,两者可成为判断ENK-TCL预后的有效指标。
- 结外鼻型NK/T细胞淋巴瘤 /
- mTOR /
- 4EBP1 /
- 预后
Abstract: Objective:To study the expression of mTOR and 4E-BP1 in extranodal Nasal-type NK/T-cell Lymphoma (ENKTCL) and the correlation with the clinicopathological factors and prognosis of ENKTCL.Method:Immunohistochemistry was used to detect the expresstion of mTOR and 4E-BP1 in the tissues of ENKTCL and nasal pharyngeal lymphoid hyperplasia.The relationship between the expression of mTOR and 4E-BP1 and clinicopathological features was analyzed using the Chi-square test, which including sorting clinical stage, general condition score and international prognostic index (IPI).Result:The expression rates of mTOR and 4E-BP1 in ENK-TCL were 63.9%and 58.3%respectively, and significantly higher than those (15.0%and 10.0%) in patients with nasal pharyngeal lymphoid hyperplasia (χ²=12.355, P=0.0001;χ²=12.410, P=0.0001).The positive expression rate of mTOR was linked to clinical staging, and the positive protein expressions in StageⅢandⅣwere higher than those in stageⅠandⅡ (χ²=17.902, P=0.0001).mTOR expression was related to 4E-BP1 (r=0.655, P=0.001).The positive expression rates of 4E-BP1 were linked to IPI of lymphoma (χ²=4.051, P=0.044).Conclusion:High-expressions of mTOR and 4E-BP1 in patients with ENKTCL are related to the biological progression and recurrence of ENKTCL and are malignant indicators to identify ENKTCL from nasal pharyngeal lymphoid hyperplasia.mTOR and 4E-BP1 may play important roles to assess ENKTCL prognosis.
- Extranodal Nasal-type NK/T-cell Lymphoma /
- mTOR /
- 4E-BP1 /
- prognosis

HTML全文

参考文献(20)

[1]	LI Y X, WANG H, JIN J, et al.Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma[J].Int J Radiat Oncol Biol Phys, 2012, 82:1809-1815.
[2]	李开春, 易克, 曾晓颖, 等.非霍奇金淋巴瘤预后因素的初步分析[J].中华肿瘤防治杂志, 2010, 17 (17):1371-1373.
[3]	DAVID O, JETT J, LEBEAU H, et al.Phospho-Akt overexpression in non-small cell lung cancer conferssignificant stage-independent survival disadvantage[J].Clin Cancer Res, 2004, 10:6865-6871.
[4]	SUN J, YANG Q, LU Z, et al.Distribution of lymphoid neoplasms in China:analysis of 4, 638cases according to the World Health Organization classification[J].Am J Clin Pathol, 2012, 138:429-434.
[5]	LIAO Y, DU X B, ZOU Q F, et al.Extranodal natural killer/T-cell lymphoma, nasal type:epidemiology study[J].Chinese-German J Clin Oncol, 2012, 11:290-293.
[6]	陆明深, 李凡彩, 侯巧燕.鼻型NK/T细胞淋巴瘤23例临床病理分析[J].临床耳鼻咽喉头颈外科杂志, 2009, 23 (2):57-59.
[7]	何小金, 田澄, 杨冬梅, 等.耳鼻咽喉头颈部216例结外非霍奇金淋巴瘤的临床病理分析[J].临床耳鼻咽喉头颈外科杂志, 2009, 23 (19):878-880.
[8]	SUZUKI R.NK/T-cell lymphomas:pathobiology, prognosis and treatment paradigm[J].Curr Oncol Rep, 2012, 14:395-402.
[9]	SANCAK Y, BAR-PELED L, ZONCU R, et al.Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids[J].Cell, 2010, 141:290-303.
[10]	MORI H, INOKI K, MASUTANI K, et al.The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential[J].Biochem Biophys Res Commun, 2009, 384:471-475.
[11]	MAITY A, BERNHARD E J.Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy[J].Cancer Res, 2010, 70:2141-2145.
[12]	WANG Z, ZHENG T, WU Q, et al.Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma[J].Neoplasma, 2012, 59:137-141.
[13]	CHEN X L, FU J P, SHI J, et al.CXC195 induces apoptosis and endoplastic reticulum stress in humanhepatocellular carcinoma cells by inhibiting the PI3K/Akt/mTOR signalingpathway[J].Mol Med Rep, 2015, 12:8229-8236.
[14]	PAN S T, QIN Y, ZHOU Z W, et al.Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38MAPK-and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells[J].Drug Des Devel Ther, 2015, 9:1601-1626.
[15]	MULLER A, ZANG C, CHUMDURI C, et al.Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1in mantle cell lymphoma[J].Int J Cancer, 2013, 133:1813-1824.
[16]	YANG Y, ZHANG Y J, ZHU Y, et al.Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasaltype:a multicenter study[J].Leukemia, 2015, 29:1571-1577.
[17]	WANG D, CHEN J, GUO F, et al.Clinical significance of mTOR and p-mTOR protein expression in human colorectal carcinomas[J].Asian Pac J Cancer Prev, 2011, 12:2581-2584.
[18]	NO J H, JEON Y T, PARK I A, et al.Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer[J].Gynecol Oncol, 2011, 121:8-12.
[19]	KASAJIMA A, PAVEL M, DARB-ESFAHANI S, et al.mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumors[J].Endocr Relat Cancer, 2011, 18:181-192.
[20]	DARB-ESFAHANI S1, FAGGAD A, NOSKE A, et al.Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma:association with stage and grade in vivo and link with response to rapamycin treatment invitro[J].J Cancer Res Clin Oncol, 2009, 135:933-941.